Elite Markets for Young‑Blood Therapy

Wealthy individuals are creating private demand for unproven anti‑aging interventions (notably 'young‑blood' transfusions), which spurs clinics and companies to commercialize preliminary animal findings into consumer treatments. That private market pressure reshapes research incentives, normalizes dubious therapies, and sidelines public oversight and funding for rigorous aging science. — This trend raises ethical, regulatory, and inequality issues: it can misallocate scientific effort, amplify medical misinformation, and create a two‑tier health market where the rich buy speculative longevity at public cost.